Advertisement
Canada markets closed
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7301
    +0.0003 (+0.04%)
     
  • CRUDE OIL

    82.68
    -0.13 (-0.16%)
     
  • Bitcoin CAD

    88,370.00
    -3,103.43 (-3.39%)
     
  • CMC Crypto 200

    1,393.30
    -30.80 (-2.16%)
     
  • GOLD FUTURES

    2,329.10
    -9.30 (-0.40%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ futures

    17,480.00
    -184.50 (-1.04%)
     
  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • NIKKEI 225

    37,932.92
    -527.16 (-1.37%)
     
  • CAD/EUR

    0.6816
    -0.0003 (-0.04%)
     

Stocks in play: Revive Therapeutics Ltd

Announced today that the U.S. Food & Drug Administration has granted the Company’s Type C meeting request to obtain agreement on the revised protocol endpoints for the Company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. The goal date for the FDA to provide its written responses is March 7, 2023. The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 at this time. Revive Therapeutics Ltd shares C.RVV are trading up 4.5% at $0.11.

Read: